Aktienanalyse zu OrthoPediatrics Corp (KIDS)KIDSOrthoPediatrics Corp

OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

OrthoPediatrics Corp (KIDS) is a good buy right now due to its recent launch of the 3P Pediatric Hip System, which has already seen over 350 surgical implantations, indicating strong demand. The current price of $23.65 is below the analyst price target of $29, representing a potential upside of 22.5%. Additionally, the company reported a Q2 revenue of $70.51 million, a 15.4% year-over-year increase, which reflects strong market performance despite ongoing net income losses. The main risk is the negative earnings per share (EPS) of -0.30, which highlights ongoing profitability challenges.

4 analysts cover KIDS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 23.00.